NASDAQ:APTO
Aptose Biosciences Stock News
$1.22
+0.0600 (+5.17%)
At Close: Apr 26, 2024
Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:30am, Friday, 06'th Aug 2021
Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Aptose: High Risk, High Reward. Watch Its Phase I Studies
06:25pm, Thursday, 05'th Aug 2021
Aptose's second quarter update was undramatic, with management indicating that they've fully enrolled their Phase I luxeptinib studies at 750mg and are moving on to 900mg. Dose escalation awaits in th
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2021 Results - Earnings Call Transcript
11:30pm, Tuesday, 03'rd Aug 2021
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2021 Results - Earnings Call Transcript
Aptose Reports Results for the Second Quarter 2021
04:01pm, Tuesday, 03'rd Aug 2021
- Conference call and webcast at 5:00 pm EDT today -
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
04:01pm, Tuesday, 20'th Jul 2021
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underl
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
02:17pm, Friday, 11'th Jun 2021
Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed o
Aptose Presents Highlights from EHA During Corporate Update Event
07:55am, Friday, 11'th Jun 2021
SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated
Aptose: Cancer Trial Catalyst Ahead At EHA21
02:29pm, Thursday, 10'th Jun 2021
APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib.
Biotech Penny Stocks To Watch For June 2021
10:24am, Sunday, 06'th Jun 2021
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
04:30pm, Tuesday, 01'st Jun 2021
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated
Aptose to Hold Corporate Update Friday, June 11th
07:30am, Thursday, 27'th May 2021
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
09:47am, Monday, 17'th May 2021
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Aptose to Present at Upcoming Investor Conferences
07:30am, Wednesday, 12'th May 2021
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly
Aptose Biosciences Inc. (APTO) CEO William Rice on Q1 2021 Results - Earnings Call Transcript
07:46pm, Tuesday, 04'th May 2021
Aptose Biosciences Inc. (APTO) CEO William Rice on Q1 2021 Results - Earnings Call Transcript
Aptose Reports Results for the First Quarter 2021
04:01pm, Tuesday, 04'th May 2021
- Conference call and webcast at 4:30 pm EDT today -
